Tenax Therapeutics reports results of 2026 annual shareholder meeting

TENAX THERAPEUTICS, INC.

Stockholders elected seven directors: June Almenoff (17.36M for), Michael Davidson (15.76M), Declan Doogan, Christopher T. Giordano, Robyn M. Hunter, Gerald T. Proehl, Stuart Rich.
Auditor Cherry Bekaert LLP ratified with 21.30M for, 3,688 against, 11,073 abstain, no broker non-votes.
All director nominees received over 17.3 million votes in favor except Michael Davidson with 15.76 million.
The meeting was held on June 2, 2026; results filed June 4, 2026.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

TENAX THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Cherry Bekaert LLP as Independent Registered Public Accounting Firm at the 2026-06-02 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-02

Exact text from the filing

The Company’s stockholders ratified the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 by the votes indicated below.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

TENAX THERAPEUTICS, INC. shareholders approved Election of Directors at the 2026-06-02 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-02

Exact text from the filing

The Company’s stockholders elected each of the following individuals to the Company’s Board of Directors for a one-year term expiring in 2027, or until his or her successor is duly elected and qualified, by the votes indicated below.

View on SEC.gov

1591 shareholder votes filed in the last 30 days. Browse all shareholder votes →

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-257400

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.